Avita Medical says data shows hospital stay reduction with RCELL System

AVITA Medical (RCEL) reaffirmed real-world data from the U.S. national burn registry demonstrating that the use of the RECELL System significantly reduces hospital length of stay by an average of 36% compared to traditional split thickness skin grafts in adult patients with deep partial thickness burns affecting up to 30% total body surface area. A greater proportion of RECELL-treated patients were discharged directly home, indicating improved recovery trajectories. RECELL harnesses the regenerative properties of a patient’s own skin to create an autologous skin cell suspension autograft, enabling clinicians to deliver a transformative solution at the point of care. In a matched analysis of 741 adults from the Burn Care Quality Platform registry, patients treated with RECELL experienced an average 5.6-day reduction in hospital LOS, a 36% decrease compared to those treated with STSG. The reduction in LOS achieved upon the use of RECELL is not only clinically meaningful but also economically impactful. Based on an estimated average daily inpatient bed cost of $7,554, the use of RECELL is associated with potential per patient cost savings exceeding $42,000, exclusive of procedure and rehabilitation costs. Furthermore, the reduction in LOS may enable hospitals to treat 13 more patients per bed annually compared to treatment with STSG alone.